Jubilant Pharmova has informed that the information as required under Regulation 30 of the Listing Regulations read with Schedule III and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 with respect to receipt of an order from Income tax department in the case of Jubilant Generics (a wholly owned step-down Indian subsidiary) of the company is enclosed as Annexure A. The Company believes that the impugned tax demand raised vide such orders suffers from mistakes apparent from records and also has been made ignoring contentions of the company. Hence, the Company is in the process of filing necessary rectification application and/or appeal in relation thereto. Post such redressal process, impugned tax demand so raised is likely to get deleted. Date and time of occurrence of event is July 26, 2024, 02:43 PM (IST). The above-mentioned document will be simultaneously posted on the Company's website at www.jubilantpharmova.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: